TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Vistusertib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms TAX-TORC
- 06 Jun 2017 Results from dose-escalation followed by dose-expansion part of the study in patients with ovarian cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 11 Oct 2016 Results (n=20) presented at the 41st European Society for Medical Oncology Congress
- 05 Mar 2016 Accrual to date is 62% according to United Kingdom Clinical Research Network record.